WO2004108157A3 - Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders - Google Patents

Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders Download PDF

Info

Publication number
WO2004108157A3
WO2004108157A3 PCT/US2004/017049 US2004017049W WO2004108157A3 WO 2004108157 A3 WO2004108157 A3 WO 2004108157A3 US 2004017049 W US2004017049 W US 2004017049W WO 2004108157 A3 WO2004108157 A3 WO 2004108157A3
Authority
WO
WIPO (PCT)
Prior art keywords
gdf8
myostatin
corticosteroids
inhibitors
conjunction
Prior art date
Application number
PCT/US2004/017049
Other languages
French (fr)
Other versions
WO2004108157A2 (en
WO2004108157A8 (en
WO2004108157B1 (en
Inventor
Lise-Anne Whittemore
Xiangping Li
Original Assignee
Wyeth Corp
Lise-Anne Whittemore
Xiangping Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Lise-Anne Whittemore, Xiangping Li filed Critical Wyeth Corp
Priority to CA002526669A priority Critical patent/CA2526669A1/en
Priority to AU2004245025A priority patent/AU2004245025A1/en
Priority to EP04753802A priority patent/EP1635870A2/en
Priority to MXPA05012965A priority patent/MXPA05012965A/en
Priority to JP2006515022A priority patent/JP5110877B2/en
Priority to BRPI0410927-9A priority patent/BRPI0410927A/en
Publication of WO2004108157A2 publication Critical patent/WO2004108157A2/en
Publication of WO2004108157A3 publication Critical patent/WO2004108157A3/en
Publication of WO2004108157B1 publication Critical patent/WO2004108157B1/en
Priority to NO20056252A priority patent/NO20056252L/en
Publication of WO2004108157A8 publication Critical patent/WO2004108157A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The disclosure provides methods for treating neuromuscular disorders in mammals. The disclosed methods include administering therapeutically effective amounts of a GDF-8 inhibitor and a corticosteroid to a subject susceptible to, or having, a neuromuscular disorder, so as to maintain desirable levels of muscle function.
PCT/US2004/017049 2003-06-02 2004-06-01 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders WO2004108157A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002526669A CA2526669A1 (en) 2003-06-02 2004-06-01 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
AU2004245025A AU2004245025A1 (en) 2003-06-02 2004-06-01 Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EP04753802A EP1635870A2 (en) 2003-06-02 2004-06-01 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
MXPA05012965A MXPA05012965A (en) 2003-06-02 2004-06-01 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders.
JP2006515022A JP5110877B2 (en) 2003-06-02 2004-06-01 Use of myostatin (GDF8) inhibitors in combination with corticosteroids to treat neuromuscular disorders
BRPI0410927-9A BRPI0410927A (en) 2003-06-02 2004-06-01 therapeutic and prophylactic methods for neuromuscular disorders
NO20056252A NO20056252L (en) 2003-06-02 2005-12-30 Therapeutic and prophylactic methods for neuromuscular disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47460303P 2003-06-02 2003-06-02
US60/474,603 2003-06-02

Publications (4)

Publication Number Publication Date
WO2004108157A2 WO2004108157A2 (en) 2004-12-16
WO2004108157A3 true WO2004108157A3 (en) 2005-02-17
WO2004108157B1 WO2004108157B1 (en) 2005-04-14
WO2004108157A8 WO2004108157A8 (en) 2006-11-16

Family

ID=33511616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017049 WO2004108157A2 (en) 2003-06-02 2004-06-01 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders

Country Status (16)

Country Link
US (2) US7785587B2 (en)
EP (1) EP1635870A2 (en)
JP (2) JP5110877B2 (en)
KR (1) KR20060026860A (en)
CN (1) CN1829532A (en)
AU (1) AU2004245025A1 (en)
BR (1) BRPI0410927A (en)
CA (1) CA2526669A1 (en)
CO (1) CO5660274A2 (en)
EC (1) ECSP066268A (en)
MX (1) MXPA05012965A (en)
NO (1) NO20056252L (en)
RU (1) RU2322261C2 (en)
UA (1) UA85055C2 (en)
WO (1) WO2004108157A2 (en)
ZA (1) ZA200510456B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
MEP57508A (en) 2002-12-20 2011-05-10 Amgen Inc Binding agents which inhibit myostatin
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
KR20060026860A (en) * 2003-06-02 2006-03-24 와이어쓰 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
JP2007526337A (en) 2004-03-02 2007-09-13 アクセルロン ファーマ インコーポレーテッド ALK7 and myostatin inhibitors and uses thereof
US7709605B2 (en) 2004-07-23 2010-05-04 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AP2007004243A0 (en) * 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
DK2407486T3 (en) * 2005-08-19 2018-02-19 Wyeth Llc Antagonist antibodies to GDF-8 and uses in the treatment of ALS and other GDF-8-associated disorders
CN101277976B (en) 2005-10-06 2012-04-11 伊莱利利公司 Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CN105001320A (en) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1968621A2 (en) * 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
ES2373246T3 (en) 2006-08-11 2012-02-01 Prosensa Technologies B.V. COMPLEMENTARY MONOCATENARY OLIGONUCLEOTIDES OF REPETITIVE ELEMENTS FOR THE TREATMENT OF GENETIC DISORDERS ASSOCIATED WITH THE INSTABILITY OF DNA REPETITIONS.
BRPI0716249A2 (en) * 2006-09-05 2013-09-03 Lilly Co Eli antimiostatin antibodies
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR101831534B1 (en) 2006-12-18 2018-02-22 악셀레론 파마 인코포레이티드 Activin-actrii antagonists and uses for increasing red blood cell levels
ES2415666T3 (en) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIa antagonists for use in the prevention or treatment of breast cancer metastases or bone loss related to breast cancer
TW201940502A (en) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
TWI667038B (en) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 Pharmaceutical composition comprising an actriia-fc fusion protein; use of an actriia-fc fusion protein for treatment or prevention of cancer-related bone loss; use of an actriia-fc fusion protein for the treatment or prevention of multiple myeloma
TWI454479B (en) 2007-03-06 2014-10-01 Amgen Inc Variant activin receptor polypeptides and uses thereof
NZ582521A (en) 2007-07-12 2011-09-30 Prosensa Technologies Bv A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue
JP2010533170A (en) 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
EP2249874A1 (en) 2008-02-08 2010-11-17 ProSensa Holding BV Methods and means for treating dna repeat instability associated genetic disorders
LT2708559T (en) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
KR20180073706A (en) 2008-06-26 2018-07-02 악셀레론 파마 인코포레이티드 Methods for dosing an activin-actriia antagonist and monitoring of treated patients
PT3750552T (en) 2008-08-14 2023-06-28 Acceleron Pharma Inc Gdf traps
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EA201100832A1 (en) 2008-11-26 2011-12-30 Амген Инк. OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR APPLICATION
WO2010083034A1 (en) * 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
AR076402A1 (en) * 2009-04-27 2011-06-08 Novartis Ag COMPOSITIONS AND METHODS TO INCREASE MUSCLE GROWTH
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
MX2011013364A (en) 2009-06-12 2012-03-16 Acceleron Pharma Inc Truncated actriib-fc fusion proteins.
US8945511B2 (en) * 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
IN2012DN02766A (en) * 2009-09-09 2015-09-18 Acceleron Pharma Inc
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy
ES2579311T3 (en) * 2010-01-15 2016-08-09 Rigel Pharmaceuticals, Inc. Scan test using DEX and GDF8
US20110268736A1 (en) * 2010-04-30 2011-11-03 Children's Medical Center Corporation Method for treating congenital myopathy
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc Actriia binding agents and uses thereof
TWI812066B (en) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
AU2013212758A1 (en) 2012-01-27 2014-08-14 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
WO2013177176A1 (en) * 2012-05-22 2013-11-28 University Of Massachusetts Compositions and methods for inducing myoblast differentiation and myotube formation
JP6433889B2 (en) 2012-06-15 2018-12-05 ファイザー・インク Improved antagonistic antibodies against GDF-8 and uses thereof
TW202237660A (en) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
KR102279522B1 (en) 2012-11-02 2021-07-19 셀진 코포레이션 Activin-actrii antagonists and uses for treating bone and other disorders
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US20140329762A1 (en) * 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
JP2016521283A (en) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Compositions and methods for growth factor modulation
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
JP6509852B2 (en) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド Constructs of growth differentiation factor 15 (GDF-15)
AU2015269333B2 (en) 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
WO2016090077A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
KR102650420B1 (en) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
KR20170129233A (en) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 Polistatin-related fusion proteins and uses thereof
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
BR112017022658A2 (en) 2015-04-22 2018-07-17 Alivegen Usa Inc isolated protein, isolated nucleic acid molecule, recombinant vector, host cell, method of producing a hybrid actriib protein, pharmaceutical composition, methods of treating myostatin or activin-related disorders, muscle wasting disease, disease cardiovascular disease, metabolic disorders, cancer cells, kidney disease, inflammatory / autoimmune disease, fibrosis disease, anemia, pain, aging condition, bone disorders, muscle wasting or metabolic disorder or fibrotic or inflammatory or activin-related in individuals, and a method of inducing stem cell growth for tissue repair or organ regeneration in an individual
KR20170074604A (en) 2015-12-22 2017-06-30 삼성전자주식회사 Composition for preventing or treating muscle wasting-related disease and use thereof
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP6987072B2 (en) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド Activin type 2 receptor binding protein and its use
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
CN111787981A (en) 2018-03-01 2020-10-16 瑞泽恩制药公司 Method of altering body composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029105A1 (en) * 2000-10-05 2002-04-11 North Shore Long Island Jewish Research Institute INHIBITION OF TGF-β AND USES THEREOF
US20020150577A1 (en) * 1994-07-08 2002-10-17 Johns Hopkins University School Of Medicine Use of antibodies specific for growth differentiation factor-11
WO2003027248A2 (en) * 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US150577A (en) * 1874-05-05 Improvement in grain-separators
US4370976A (en) * 1980-06-03 1983-02-01 Contour Fabricators, Inc. Dynamic foam orthosis
US5130141A (en) * 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
GB9211085D0 (en) * 1992-05-23 1992-07-08 Tippey Keith E Electrical stimulation
US6673534B1 (en) * 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK0690873T3 (en) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Growth Differentiation Factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
DK0698094T3 (en) 1993-05-12 2004-05-03 Inst Genetics Llc BMP-11 compositions
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
PT716610E (en) 1993-08-26 2006-08-31 Genetics Inst Llc MORPHOGENETIC PROTEINS OF BONES FOR HUMANS TO BE USED IN NEURAL REGENERATION
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
DE69841139D1 (en) 1997-07-14 2009-10-22 Univ Liege MUTATIONS IN MYOSTATINGEN INCREASE MUSCLE MASS IN MAMMALS
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
JP4544742B2 (en) 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Treatment of diabetes by inhibition of GDF-8
IL141330A0 (en) 1998-08-20 2002-03-10 Regeneron Pharma Dcr5, a bmp-binding protein and aplications thereof
CN100567322C (en) 1999-01-21 2009-12-09 梅塔莫菲克斯公司 Suppress the active polypeptide of growth and differentiation factor and express the cell of this polypeptide
AU778470B2 (en) 1999-07-20 2004-12-09 Pharmexa A/S Method for down-regulating GDF-8 activity
AU2001241817A1 (en) 2000-02-29 2001-09-12 Zymogenetics Inc. Kunitz domain polypeptide zkun8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US6552172B2 (en) 2001-08-30 2003-04-22 Habto Biotech, Inc. Fibrin nanoparticles and uses thereof
MXPA04008149A (en) 2002-02-21 2005-06-17 Wyeth Corp Follistatin domain containing proteins.
MXPA04008150A (en) 2002-02-21 2005-06-17 Wyeth Corp A follistatin domain containing protein.
WO2004024092A2 (en) 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
MEP57508A (en) 2002-12-20 2011-05-10 Amgen Inc Binding agents which inhibit myostatin
KR20060026860A (en) * 2003-06-02 2006-03-24 와이어쓰 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
MX2007011400A (en) 2005-03-23 2007-10-11 Wyeth Corp Detection of gdf-8 modulating agents.
CN101137906A (en) 2005-03-23 2008-03-05 惠氏公司 Detection of an immune response to gdf-8 modulating agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150577A1 (en) * 1994-07-08 2002-10-17 Johns Hopkins University School Of Medicine Use of antibodies specific for growth differentiation factor-11
WO2002029105A1 (en) * 2000-10-05 2002-04-11 North Shore Long Island Jewish Research Institute INHIBITION OF TGF-β AND USES THEREOF
WO2003027248A2 (en) * 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GRANCHELLI J A ET AL: "Pre-clinical screening of drugs using the mdx mouse.", NEUROMUSCULAR DISORDERS : NMD. JUN 2000, vol. 10, no. 4-5, June 2000 (2000-06-01), pages 235 - 239, XP002305261, ISSN: 0960-8966 *
HILL JENNIFER J ET AL: "The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 43, 25 October 2002 (2002-10-25), pages 40735 - 40741, XP002305260, ISSN: 0021-9258 *
HUDECKI M S ET AL: "Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice.", RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY. JAN 1993, vol. 79, no. 1, January 1993 (1993-01-01), pages 45 - 60, XP009039770, ISSN: 0034-5164 *
KHURANA TEJVIR S ET AL: "Pharmacological strategies for muscular dystrophy.", NATURE REVIEWS. DRUG DISCOVERY. MAY 2003, vol. 2, no. 5, May 2003 (2003-05-01), pages 379 - 390, XP009039735, ISSN: 1474-1776 *
LANG CHARLES H ET AL: "Regulation of myostatin by glucocorticoids after thermal injury", FASEB JOURNAL, vol. 15, no. 10, August 2001 (2001-08-01), pages 1807 - 1809, XP002305301, ISSN: 0892-6638 *
LEE SE-JIN ET AL: "Regulation of myostatin activity and muscle growth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 16, 31 July 2001 (2001-07-31), pages 9306 - 9311, XP002281005, ISSN: 0027-8424 *
MERLINI LUCIANO ET AL: "Early prednisone treatment in Duchenne muscular dystrophy.", MUSCLE AND NERVE, vol. 27, no. 2, February 2003 (2003-02-01), pages 222 - 227, XP009039797, ISSN: 0148-639X *
MUNTONI FRANCESCO ET AL: "Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research.", NEUROMUSCULAR DISORDERS : NMD. OCT 2002, vol. 12 Suppl 1, October 2002 (2002-10-01), pages S162 - S165, XP002305263, ISSN: 0960-8966 *
WAGNER KATHRYN R ET AL: "Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.", ANNALS OF NEUROLOGY, vol. 52, no. 6, December 2002 (2002-12-01), pages 832 - 836, XP009039801, ISSN: 0364-5134 *
WHITTEMORE LISA-ANNE ET AL: "Inhibition of myostatin in adult mice increases skeletal muscle mass and strength.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 300, no. 4, 24 January 2003 (2003-01-24), pages 965 - 971, XP002305259, ISSN: 0006-291X *

Also Published As

Publication number Publication date
ECSP066268A (en) 2006-07-28
EP1635870A2 (en) 2006-03-22
AU2004245025A1 (en) 2004-12-16
RU2005141434A (en) 2006-07-10
KR20060026860A (en) 2006-03-24
US20050014733A1 (en) 2005-01-20
JP2007238631A (en) 2007-09-20
US7785587B2 (en) 2010-08-31
JP5110877B2 (en) 2012-12-26
ZA200510456B (en) 2009-05-27
WO2004108157A2 (en) 2004-12-16
NO20056252L (en) 2005-12-30
CN1829532A (en) 2006-09-06
BRPI0410927A (en) 2006-06-27
WO2004108157A8 (en) 2006-11-16
UA85055C2 (en) 2008-12-25
WO2004108157B1 (en) 2005-04-14
JP2006527193A (en) 2006-11-30
US20100322942A1 (en) 2010-12-23
RU2322261C2 (en) 2008-04-20
CA2526669A1 (en) 2004-12-16
MXPA05012965A (en) 2006-03-09
CO5660274A2 (en) 2006-07-31

Similar Documents

Publication Publication Date Title
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005009349A3 (en) Composition and method for treating neurological disorders
WO2005023179A3 (en) Combination methods of treating cancer
WO2007112345A8 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2006020884A3 (en) Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
MXPA05013900A (en) Use of brimonidine for preventing and reducing the severity of stress-associated conditions.
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2006009975A3 (en) Histamine to treat disorders affecting muscle function
WO2004062623A3 (en) Method of treating functional bowel disorders
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
GB2396108B (en) Treatment of pain
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022134.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050201

WWE Wipo information: entry into national phase

Ref document number: 172062

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2526669

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012965

Country of ref document: MX

Ref document number: 2006515022

Country of ref document: JP

Ref document number: 12005502152

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020057023105

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 543942

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004245025

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004245025

Country of ref document: AU

Date of ref document: 20040601

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004753802

Country of ref document: EP

Ref document number: 200510456

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004245025

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2732/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005141434

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 05131698

Country of ref document: CO

Ref document number: 1200501950

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: CR2006-008169

Country of ref document: CR

WWP Wipo information: published in national office

Ref document number: 2004753802

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057023105

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0410927

Country of ref document: BR